Anaplastic large cell lymphoma: A potential pitfall in the differential diagnosis of melanoma

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 2, 2013, Pages 280-283

  Pulitzer, Melissa ^a   Brady, Mary Sue ^a   Blochin, Elen ^a   Amin, Bijal ^b   Teruya Feldstein, Julie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITF PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

AGED; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; SKIN TUMOR;

AGED; ANTIGENS, CD30; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 84874744511     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0532-CR     Document Type: Article

References (19)

1. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30- positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15): 4024-4035.
2. Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignant melanoma. Cancer. 1999;86(11): 2252-2258.
3. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997;79(12): 2361-2370.
4. Callaway MP, Briggs JC. The incidence of late recurrence (greater than 10 years): an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg. 1989;42(1): 46-49.
5. Bouffard D, Barnhill RL, Mihm MC, Sober AJ. Very late metastasis (27 years) of cutaneous malignant melanoma arising inahalo giant congenital nevus. Dermatology. 1994;189(2): 162-166.
6. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg. 1990;212(2): 173-177.
7. Ng WK, Ip P, Choy C, Collins RJ. Cytologic and immunocytochemical findings of anaplastic large cell lymphoma. Cancer. 2003;99(1): 33-43.
8. Stein H, Foss HD, Durkop H et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12): 3681-3695.
9. Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A and MAGE-1 in HMB-45 negative melanomas. Am J Surg Pathol. 2002;26(1): 82-87.
10. Miettinen M, Franssila K. Immunohistochemical spectrum of malignant melanoma: the common presence of keratins. Lab Invest. 1989;61(6): 623-628.
11. Jager E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997;71(2): 142-147.
12. Guerriere-Kovach P, Hunt EL, Patterson JW, Glembocki DJ, English JC, Wick MR. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol. 2004;122(1): 70-77.
13. Janku F, Novotny J, Julis I, et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res. 2005;15(4): 251-256.
14. Isabel Zhu Y, Fitzpatric JE. Expression of c-kit (CD-117) in Spitz nevus and malignant melanoma. J Cutan Pathol. 2006;33(1): 33-37.
15. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol. 1997;10(9): 939-944.
16. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis withareference to CD117 (KIT). Mod Pathol. 2000;13(10): 1134-1142.
17. Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood. 1994;83(3): 785-792.
18. Brauns TC, Schultewolter T, Dissemond J, Maschke J, Goos M. C-Kit expression in primary cutaneous T-cell lymphomas. J Cutan Pathol. 2004;31(9): 577-582.
19. Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol. 2004;17(8): 946-953.